NextPlat Beats On EPS, But Q3 Breaks The Sequential Recovery And Misses Management's Profitability Target

NextPlat Corp. (NASDAQ: NXPL) reported a third-quarter loss of $0.28 per share, 39.1% better than the consensus estimate of a $0.46 loss. Revenue tells a different story. Sales of $10.5 million missed the $13.0 million consensus by 19.2% and fell 23.7% year over year. Earnings Whispers' normalized comparison shows earnings fell 250.0% year over year. On a reported GAAP basis, however, the net loss narrowed about 66%, to $0.7 million from $2.2 million, or from $0.84 per share a year ago. Both readings are part of the record. The central tension is that the year-over-year comparison still looks like a turnaround, while the sequential trend moved backward in a quarter management had framed as the start of bottom-line profitability.

The quality of the beat deserves scrutiny. The narrower loss came largely from mix and cost discipline rather than growth. Consolidated gross margin reached roughly 35%, up from 19.9% a year earlier. Healthcare gross margin rose to about 41% from 18%. Total operating expenses fell to $4.5 million from $4.9 million, helped by $0.3 million less payroll and the absence of a $0.25 million litigation charge from last year. The strategic pivot is visible in the healthcare mix:

• Pharmacy contract revenue quadrupled to $2.4 million, driven by 340B work.
• 340B prescription volumes grew nearly 72%.
• Pharmacy prescription revenue collapsed to $4.3 million from $9.5 million on lower reimbursement rates and retail volumes.

E-commerce was steady, up 3% to $3.8 million at a stable 24% gross margin, with record airtime revenue.

The call is where the narrative weakened. Measured against the second quarter, nearly every key line deteriorated:

• Revenue slipped to $10.5 million from $11.9 million. The Q2 call had anticipated sequential growth.
• Healthcare revenue fell to $6.7 million from $7.8 million.
• Healthcare gross margin fell to about 41% from 46%, mainly because a high-margin medication fulfillment customer permanently closed one of its two facilities.
• Consolidated gross margin retreated from a record 40% back to Q1's 35%.
• Operating loss widened to $0.8 million from just $0.127 million.
• Combined segment income shrank to roughly $0.2 million from about $1.2 million.
• Contracted pharmacy revenue declined sequentially for the first time after rising 20% in Q2.
• New 340B signings slowed to three, from six in Q2 and five in Q1.
• Clinics bringing fulfillment in-house continue to drain retail volumes.

Management's tone shifted accordingly. The Q2 message of a largely completed turnaround with profitability from Q3 gave way to talk of "volatility" and "still work to do," and the profitability expectation was not reiterated.

The forward catalysts are real but mostly prospective. Scott's Pharmacy in the Pensacola area closed October 1. Management guided it to roughly $1.2 million in quarterly revenue and about $150,000 in net profit in Q4, with margins running ahead of plan. Other developments include:

• A new Jacksonville location has opened.
• The three new 340B contracts, 14 year to date, are expected to contribute in early 2027.
• E-commerce reach expanded through Decathlon in 20 countries, plus Mountain Warehouse and Easy Shop.
• A point-of-care dispensing kiosk initiative is underway.

Bears have legitimate ammunition, though. The nationwide healthcare e-commerce site has now slipped twice, from end of Q2 to Q3 and now to November. Litigation costs persist, and cash fell to $11.2 million from $11.9 million in Q2 and $13.7 million at year-end. The balance sheet still carries no material unsecured debt and $13.5 million of working capital, so this is not a liquidity story yet. Still, the burn hasn't stopped.

The market setup is more complicated than the EPS surprise implies. Investor sentiment improved meaningfully heading into the report, moving from clearly negative (-0.32) to roughly neutral (+0.02). Shares rose 22.8% from the opening price after the August report to $8.29 and sat about 47% above the 200-day moving average. That run was built on the Q2 profitability narrative this quarter failed to deliver. The stock had also already faded about 17% from its $9.94 52-week high set September 2, so some enthusiasm had cooled before the release. The internal trend readings are mixed, with momentum positive but AVWAP negative, which fits a stock that has rallied but lost its footing.

The bottom line is that NextPlat's beat came against a low bar and rests on a margin transformation that is real year over year but slipped quarter over quarter. Revenue missed badly, the profitability timeline broke, and 340B signings and contract revenue both lost momentum. Scott's should lift Q4 revenue and volumes. However, investors who bid the shares up on a completed-turnaround thesis now need to see sequential stabilization, and an on-time e-commerce launch, before that thesis regains credibility.

Read our earnings preview for NextPlat Corp.: https://www.earningswhispers.com/article/NXPL/23039

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.